Key result
Non-Vitamin K antagonist oral anticoagulants are recommended as first-line therapy for deep vein thrombosis, offering a simpler route of administration and good efficacy and safety compared to VKAs.
Why the study?
While NOACs are first-line for DVT, questions remain regarding their efficacy and safety in high-risk populations such as patients with renal failure, active cancer, and pregnant women.
Do non-vitamin K antagonist oral anticoagulants (NOACs) provide safe and effective anticoagulation compared to vitamin K antagonists in patients with deep venous thrombosis?
Do non-vitamin K antagonist oral anticoagulants (NOACs) provide safe and effective anticoagulation compared to vitamin K antagonists in patients with deep venous thrombosis?
Answers are grounded in this paper and cite their sources.
NOACs have become the preferred first-line anticoagulation therapy for DVT, though evidence is still evolving for high-risk populations such as those with end-stage renal disease or active cancer.
Anticoagulation therapy is the cornerstone of treatment in acute vein thrombosis (DVT) and it aims to reduce symptoms, thrombus extension, DVT recurrences, and mortality. The treatment for DVT depends on its anatomical extent, among other factors. Anticoagulation therapy for proximal DVT is clearly recommended (at least for 3 months), while AT for isolated distal DVT should be considered, especially in the presence of high thromboembolic risk factors. The optimal anticoagulant and duration of therapy are determined by the clinical assessment, taking into account the thromboembolic and bleeding risk in each patient in a case-by-case decision making. Non-Vitamin K antagonists oral anticoagulants (NOACs) were a revolution in the anticoagulation management of DVT. Nowadays, NOACs are considered as first-line therapy in the anticoagulation therapy for DVT and are recommended as the preferred anticoagulant agents by most scientific societies. NOACs offer a simple route of administration (oral agents), a rapid onset-offset of their action along with a good efficacy and safety profile in comparison with Vitamin K Antagonists (VKAs). However, there are issues about their efficacy and safety profile in specific populations with high thromboembolic and bleeding risks, such as renal failure patients, active-cancer patients, and pregnant women, in which VKAs and heparins were the standard care of treatment. Since the available data are promising for the use of NOACs in end-stage chronic kidney disease and cancer patients, several ongoing randomized trials are currently trying to solve that issues and give evidence about the safety and efficacy of NOACs in these populations.
No takes yet. Share an insight, caveat, or question.
Papakonstantinou et al. (2020) conducted a review in Deep Venous Thrombosis (DVT). Non-Vitamin K antagonists oral anticoagulants (NOACs) vs. Vitamin K Antagonists (VKAs) and heparins was evaluated. Non-Vitamin K antagonist oral anticoagulants are recommended as first-line therapy for deep vein thrombosis, offering a simpler route of administration and good efficacy and safety compared to VKAs.
Synapse has enriched 10 related papers. Consider them for comparative context: